Overview
The osmotic fragility test is a laboratory assay used to assess the resistance of red blood cells to hemolysis when exposed to hypotonic saline solutions. It reflects the surface area–to–volume ratio of erythrocytes and their ability to take up water without rupturing. As this ratio decreases, red cells become more sensitive to osmotic stress and lyse at higher saline concentrations. The test is especially useful in evaluating red cell membrane disorders and certain types of anemia.
Symptoms
The osmotic fragility test itself does not cause symptoms but is performed in patients presenting with features of hemolytic or chronic anemia. These may include pallor, fatigue, jaundice, shortness of breath, splenomegaly, and recurrent episodes of anemia. In hereditary red cell disorders, symptoms may appear early in life, while in acquired conditions, they may develop gradually.
Causes
Increased osmotic fragility occurs when red blood cells have reduced membrane surface area, causing them to rupture easily in hypotonic solutions. This is classically seen in hereditary spherocytosis and may also occur in autoimmune hemolytic anemia and conditions associated with spherocyte formation, such as burns or transfusion reactions.
Decreased osmotic fragility is seen when red cells have increased membrane surface area or altered hemoglobin content, allowing them to resist hemolysis even in markedly hypotonic solutions. This pattern is observed in thalassemia, iron deficiency anemia, sickle cell anemia, liver disease, and post-splenectomy states.
Risk Factors
Genetic mutations affecting red cell membrane proteins are major risk factors for increased osmotic fragility. Chronic hemolytic states, splenic dysfunction, liver disease, and nutritional deficiencies increase the likelihood of abnormal results. Family history of anemia, early onset hemolysis, and recurrent jaundice raise suspicion for hereditary disorders evaluated by this test.
Prevention
While red cell membrane disorders cannot be prevented, early diagnosis using osmotic fragility testing helps reduce complications of chronic hemolysis. Timely treatment of anemia, nutritional deficiencies, and underlying systemic conditions improves patient outcomes. Proper sample handling, testing within recommended time limits, and correlation with peripheral blood smear and other hematological investigations ensure accurate interpretation and effective clinical management.
